The AI Summit Returns to Black Hat USA 2025 on August 5
One Day Event Hosted at Mandalay Bay in Las Vegas Features Keynotes and Workshops Focused on Future of Digital Defense
Article content
LAS VEGAS — The second annual The AI Summit at Black Hat USA 2025 is a live, in-person event taking place for one day only on August 5 at the Mandalay Bay Convention Center in Las Vegas. Featuring a packed agenda of featured speakers on topics showcasing cutting-edge AI solutions to better equip Black Hat attendees with innovative strategies to implement these AI products and tools, secure their enterprises, and prepare for future cyber attacks.
Article content
Article content
This groundbreaking event discusses the importance of AI as not only a tool but as the cornerstone of both advanced cyber defense and as the latest weapon in the hands of today's threat actors. It kicks off with keynote presentations and panel discussions on the headliner stage, before breaking into Strategic and Technical workshop tracks. These sessions empower attendees to collaboratively tackle two pivotal forces shaping today's technology landscape – artificial intelligence and cybersecurity.
Article content
'We are proud of the diverse and powerful lineup of speakers and presentations at The AI Summit at Black Hat USA 2025,' said Caroline Hicks, Senior Director, The AI Summit Series, Informa Connect. 'Covering everything from GenAI-driven offense and defense to enterprise-grade AI systems, our program showcases the full breadth of today's cybersecurity landscape. Delegates will gain practical strategies and insights from leading global experts to equip them with the knowledge and tools to enhance detection and prevention using the latest AI innovations.'
Article content
The AI Summit at Black Hat USA will bring together a range of attendees from senior enterprise executives to AI specialists, IT leaders to cybersecurity professionals, for a day of learning, networking, and inspirational moments. Topics will include the use of AI in cybersecurity products and solutions, securing AI applications and models within the enterprise, and the use of AI in cyber attacks. A preview of the stage presentations include:
Article content
The New Frontier: AI Agents & Security Risks opens the conference with Protect AI's Ian Swanson and Dan McInerney.
Addressing Real-World AI Security Challenges features panelists Jyotirmay Gadewadikar (Mitre), Rosalia Hajek (Topgolf Callaway Brands), Chuck Herrin (F5), and Niv Braun (Noma Security), among others, discussing how AI can be trusted and scaled in critical infrastructure and focusing on innovation in automation and threat detection.
Debunking AI Myths & Misconceptions: What Security Leaders Need to Know includes Nathan Hamiel (Kudelski Security), Jess Burn (Forrester) and Apostol Vassilev (National Institute of Standards and Technology) separating hype from reality to help security professionals address real risks and practical defenses.
Article content
The AI Summit at Black Hat USA 2025 is presented by Protect AI as well as sponsors Crogl, Trend Micro, World Wide Technology (WWT), Elastic, GTB Technologies, Microsoft Security, Lockheed Martin, F5, Intezer, Noma Security, and Cranium AI, among others.
Article content
To learn more about The AI Summit at Black Hat USA 2025, visit https://www.blackhat.com/us-25/ai-summit.html for passes, speaker announcements, show agenda, and sponsorship opportunities.
Article content
The AI Summit at Black Hat USA 2025 takes place on August 5 at the Mandalay Bay Convention Center in Las Vegas.
The AI Summit Series smartly integrates into the Black Hat USA 2025 programming to celebrate its 28th anniversary with a live, in-person six-day program from August 2 to August 7. As 2023 saw artificial intelligence explode into the mainstream and land firmly on the boardroom agenda, today it's clear that no AI implementation can truly be successful without understanding, and preparing for, the myriad cybersecurity implications.
Article content
ABOUT THE AI SUMMIT SERIES
Article content
In 2016, at a time when AI conferences were geared towards research & academia, Informa launched The AI Summit Series – the first-ever conference and exhibition to explore what AI practically means for enterprises. Every year since then, we've gathered top executives and investors with technology specialists and data scientists from across the globe to network, learn and showcase ground-breaking technology solutions for business.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why Are These 3 High-Yield Dividend King Stocks Near 52-Week Lows While the S&P 500 Just Hit an All-Time High?
The S&P 500 (SNPINDEX: ^GSPC) closed out the first half of the year at an all-time high -- a remarkable recovery considering how beaten down the index was in April. But not all stocks are enjoying the rebound. Dividend-paying stocks PepsiCo (NASDAQ: PEP), Kimberly-Clark (NASDAQ: KMB), and Target (NYSE: TGT) have lost value over the last three years because they aren't consistently growing their earnings and consumer spending is under pressure. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » However, these companies are Dividend Kings -- meaning they have paid and raised their payouts for over 50 consecutive years. Here's why Pepsi, Kimberly-Clark, and Target are excellent choices for folks looking to boost their passive income. Challenges are mounting for consumer-facing companies Investing is more about expectations than past performance. So the market can grow intolerant of companies that undergo multiyear periods of slowing or negative growth. That's certainly been the case for Pepsi, Kimberly-Clark, and Target. PEP Revenue (TTM) data by YCharts As the chart shows, all three companies are experiencing slow or negative sales growth, and their stock prices are falling accordingly. PepsiCo owns a variety of beverage and snack brands -- from flagship Pepsi to Gatorade, Mountain Dew, Tropicana, Frito-Lay snack brands like Lay's, Cheetos, Doritos, and Quaker Oats products. The diverse lineup helps make Pepsi a stable stalwart, but the company is seeing intense backlash from consumers who are drained from years of price increases. Pepsi has made some acquisitions focused on healthier snacks and meal replacements to diversify its product lineup. And the company is revamping marketing and packaging efforts to cater to consumers. Still, Pepsi doesn't expect these efforts to offset near-term headwinds, so its guidance is fairly weak. Kimberly-Clark makes paper-based professional products and has consumer brands such as Kleenex, Cottonelle, Viva, and Scott. It also offers a variety of adult care, baby and child care, and feminine care products. But the company is in a similar boat to Pepsi. Demand is flatlining, pressuring Kimberly-Clark's growth rate and margins. A multiyear strategy to reorganize the company has yet to produce tangible results. Target's issues are even more severe. Despite promotions and exclusive product offerings, the company is struggling to boost in-store foot traffic. Target also mismanaged its inventory and hasn't tapped into e-commerce and delivery options nearly as well as peers like Walmart. Whereas Pepsi and Kimberly-Clark sell everyday-use products, Target's product mix is more discretionary in nature -- which has backfired as consumers look for value. Stable and growing payouts Although all three companies are far from the top of their game, they are all still highly profitable. They aren't turnaround stories in dire straits. The payout ratio and free cash flow (FCF) per share compared to the dividend per share are useful metrics for gauging dividend affordability. The payout ratio is a company's earnings per share divided by the dividend per share -- with 50% to 75% generally considered a healthy range. But stable companies in non-cyclical sectors can be on the higher end of that range. As you can see in the following chart, Pepsi, Kimberly-Clark, and Target all have good payout ratios. PEP Payout Ratio data by YCharts Pepsi is earning roughly the same FCF as its dividend, but Kimberly-Clark and Target are generating boatloads more FCF than dividends -- illustrating dividend affordability. Heavily discounted valuations All three companies have seen their valuations fall considerably since they have continued to generate strong earnings, but their stock prices are down. PEP PE Ratio (10y Median) data by YCharts To be fair, when a company is producing below its historical growth rate and not living up to investor expectations, it arguably deserves to trade at a discount. However, all three companies are now down considerably from their average valuations. Pepsi's price-to-earnings (P/E) ratio is now under 20 even though it has historically been a premium-priced stock relative to the market. Similarly, investors tend to give Kimberly-Clark a slightly premium valuation given its stable and reliable dividend and recession-resistant business model. But now, the company is trading at its lowest valuation in years. Like most retailers, Target typically trades at a discount to the S&P 500. But its valuation is so cheap, the stock's P/E ratio is within striking distance of hitting single digits. Three Dividend Kings that have fallen far enough Pepsi, Kimberly-Clark, and Target stand out as excellent values, especially for patient investors looking to boost their passive income streams. Not only do these companies have exceptional track records of growing their payouts, but they can also afford their dividends thanks to strong earnings. What's more, all three companies have high yields -- Pepsi at 4.3%, Kimberly-Clark at 3.9%, and Target at 4.5%. Short-term-minded investors are making a mistake by dumping these stocks just because their results haven't been great lately. Long-term investors who can filter out the noise are getting the chance to buy these names at compelling valuations. Should you invest $1,000 in PepsiCo right now? Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor 's total average return is1,045% — a market-crushing outperformance compared to178%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Daniel Foelber has positions in PepsiCo. The Motley Fool has positions in and recommends Target and Walmart. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 28, 2025. The video was published on Jul. 2, 2025. Should you invest $1,000 in Kiniksa Pharmaceuticals International right now? Before you buy stock in Kiniksa Pharmaceuticals International, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kiniksa Pharmaceuticals International wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor 's total average return is1,045% — a market-crushing outperformance compared to178%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Hepatitis D Pipeline Insight, 2025 ' report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook Key Takeaways from the Hepatitis D Pipeline Report In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups - an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016. In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment. DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment. The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs Hepatitis D Emerging Drugs Profile Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D. Brelovitug: Bluejay Therapeutics Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D. RBD1016: Ribocure Pharmaceuticals AB RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D. The Hepatitis D Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment. Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs Hepatitis D Companies Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Hepatitis D Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers Scope of the Hepatitis D Pipeline Report Coverage- Global Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hepatitis D: Overview Pipeline Therapeutics Therapeutic Assessment Hepatitis D– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II/III) Brelovitug: Bluejay Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hepatitis D Key Companies Hepatitis D Key Products Hepatitis D- Unmet Needs Hepatitis D- Market Drivers and Barriers Hepatitis D- Future Perspectives and Conclusion Hepatitis D Analyst Views Hepatitis D Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
